Showing results (31-40 of 40) with videos related to
Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Cancer Research|March 17, 2007
Combining adoptive cellular and immunocytokine therapies to improve treatment of B-lineage malignancyHarjeet Singh, Lisa Marie Serrano, Timothy Pfeiffer, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 2, 2016
Targeting CD138-/CD20+ Clonogenic Myeloma Precursor Cells Decreases These Cells and Induces Transferable Antimyeloma ImmunityLawrence G Lum, Archana Thakur, Sri Vidya Kondadasula, et al.Bone Marrow Transplantation|January 26, 2018
Ruxolitinib: a steroid sparing agent in chronic graft-versus-host diseaseHanna Jean Khoury, Amelia A Langston, Vamsi K Kota, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 19, 2019
Summary of the Third Annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune ProfilingSarah A Holstein, Zaid Al-Kadhimi, Luciano J Costa, et al.Clinical Lymphoma, Myeloma & Leukemia|June 15, 2016
Does Post-Transplant Maintenance Therapy With Tyrosine Kinase Inhibitors Improve Outcomes of Patients With High-Risk Philadelphia Chromosome-Positive Leukemia?Zachariah DeFilipp, Amelia A Langston, Zhengjia Chen, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 27, 2013
CD20-targeted T cells after stem cell transplantation for high risk and refractory non-Hodgkin's lymphomaLawrence G Lum, Archana Thakur, Qin Liu, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 9, 2018
Peritransplantation Red Blood Cell Transfusion Is Associated with Increased Risk of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell TransplantationSakura Hosoba, Edmund K Waller, Neeta Shenvi, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 7, 2005
Efficacy of mycophenolate mofetil in the treatment of chronic graft-versus-host diseaseFrancisco Lopez, Pablo Parker, Auayporn Nademanee, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 19, 2024
Randomized Phase III SIERRA Trial of 131I-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AMLBoglarka Gyurkocza, Rajneesh Nath, Stuart Seropian, et al.The Lancet. Haematology|March 3, 2019
Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)Javier Bolaños-Meade, Ran Reshef, Raphael Fraser, et al.Pageof 4